MCID: PRT037
MIFTS: 66

Pertussis

Categories: Infectious diseases, Rare diseases, Respiratory diseases, Smell/Taste diseases

Aliases & Classifications for Pertussis

MalaCards integrated aliases for Pertussis:

Name: Pertussis 12 75 53 59 3 15 72
Whooping Cough 12 75 53 59 43 3 15 17 33
Bordetella Infections 44 17 72
Whooping Cough Due to Unspecified Organism 72
Bordetella Pertussis Infection 53
Bordetella Infection 12
Wc - Whooping Cough 12

Characteristics:

Orphanet epidemiological data:

59
whooping cough
Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:1116
MeSH 44 D001885
SNOMED-CT 68 26484003
MESH via Orphanet 45 D014917
ICD10 via Orphanet 34 A37.0 A37.1 A37.8 more
UMLS via Orphanet 73 C0043167 C0043168
Orphanet 59 ORPHA1489
UMLS 72 C0006015 C0043167 C0043168

Summaries for Pertussis

MedlinePlus : 43 Whooping cough is an infectious bacterial disease that causes uncontrollable coughing. The name comes from the noise you make when you take a breath after you cough. You may have choking spells or may cough so hard that you vomit. Anyone can get whooping cough, but it is more common in infants and children. It's especially dangerous for infants. The coughing spells can be so bad that it is hard for infants to eat, drink, or breathe. To make a diagnosis, your doctor may do a physical exam, blood tests, chest x-rays, or nose or throat cultures. Before there was a vaccine, whooping cough was one of the most common childhood diseases and a major cause of childhood deaths in the U.S. Now most cases are prevented by vaccines. If you have whooping cough, treatment with antibiotics may help if given early. Centers for Disease Control and Prevention

MalaCards based summary : Pertussis, also known as whooping cough, is related to bronchiolitis and neutrophil migration, and has symptoms including fever, pruritus and snoring. An important gene associated with Pertussis is TLR4 (Toll Like Receptor 4), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Montelukast and Pentetic acid have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, smooth muscle and endothelial, and related phenotypes are homeostasis/metabolism and hematopoietic system

Disease Ontology : 12 A commensal bacterial infectious disease that results in inflammation located in respiratory tract, has material basis in Bordetella pertussis, or has material basis in Bordetella parapertussis, which produce toxins that paralyze the cilia of the respiratory epithelial cells. The infection is characterized by a prolonged, high-pitched, deeply indrawn breath (whoop).

CDC : 3 Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Pertussis is known for uncontrollable, violent coughing which often makes it hard to breathe. After cough fits, someone with pertussis often needs to take deep breaths, which result in a "whooping" sound. Pertussis can affect people of all ages, but can be very serious, even deadly, for babies less than a year old. The best way to protect against pertussis is by getting vaccinated

Wikipedia : 75 Whooping cough, also known as pertussis or 100-day cough, is a highly contagious bacterial disease.... more...

Related Diseases for Pertussis

Diseases related to Pertussis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 585)
# Related Disease Score Top Affiliating Genes
1 bronchiolitis 30.9 TNF TLR4 IL6 IL10
2 neutrophil migration 30.9 MAPK1 ITGB2 ITGAM
3 autoimmune disease 30.8 TNF IL6 IL1B IL10
4 typhoid fever 30.8 TNF TLR4 IL6 IL1B
5 post-transplant lymphoproliferative disease 30.7 TNF IL6 IL10
6 acute respiratory distress syndrome 30.6 TNF IL6 IL1B
7 sudden infant death syndrome 30.6 TNF IL6 IL1B IL10
8 laryngitis 30.6 TNF IL6 IL1B
9 morphine dependence 30.6 OPRM1 FOS ADCY10
10 legionellosis 30.6 TNF TLR4 IL1B
11 autoimmune uveitis 30.5 TNF IL1B IL10
12 pneumonia 30.5 TNF TLR4 IL6 IL1B IL10
13 chorioamnionitis 30.5 TNF TLR4 IL6 IL1B
14 pulmonary edema 30.3 TNF IL1B IL10
15 meningitis 30.3 TNF IL6 IL1B IL10
16 chlamydia 30.3 TNF TLR4 IL6 IL1B IL10
17 lung disease 30.3 TNF IL6 IL1B IL10
18 myocarditis 30.3 TNF ITGB2 IL6
19 hematopoietic stem cell transplantation 30.2 TNF IL6 IL10
20 otitis media 30.2 TNF TLR4 IL6 IL1B IL10
21 cerebral palsy 30.2 TNF IL6 IL1B
22 perinatal necrotizing enterocolitis 30.1 TNF TLR4 IL6 IL1B
23 aseptic meningitis 30.1 TNF IL1B IL10
24 human immunodeficiency virus type 1 30.1 TNF MAPK10 MAPK1 IL6 IL10
25 gastroenteritis 30.1 TNF IL6 IL1B IL10
26 peptic ulcer disease 30.1 TNF IL1B IL10
27 proteasome-associated autoinflammatory syndrome 1 30.1 TNF TLR4 IL6 IL1B IL10
28 transverse myelitis 30.0 TNF IL6 IL10
29 endometritis 30.0 TNF IL6 IL1B
30 bacterial infectious disease 30.0 TNF TLR4 ITGAM IL6 IL1B IL10
31 toxic shock syndrome 30.0 TNF TLR4 IL6 IL1B IL10
32 cystitis 30.0 TNF TLR4 IL6
33 tonsillitis 30.0 TNF IL6 IL1B
34 appendicitis 30.0 TNF IL6 IL1B IL10
35 bacterial meningitis 30.0 TNF IL6 IL1B IL10
36 human immunodeficiency virus infectious disease 30.0 TNF IL6 IL10
37 contact dermatitis 30.0 TNF IL6 IL1B IL10
38 inflammatory bowel disease 29.9 TNF TLR4 IL6 IL1B IL10
39 lyme disease 29.9 TNF IL6 IL1B
40 brucellosis 29.9 TNF TLR4 IL6 IL10
41 endocarditis 29.9 TNF IL6 IL10
42 cytomegalovirus infection 29.8 TNF IL6 IL1B
43 arthritis 29.8 TNF IL6 IL1B IL10
44 aphthous stomatitis 29.8 TNF IL6 IL1B IL10
45 viral encephalitis 29.8 TNF IL6 IL1B IL10
46 synovitis 29.7 TNF IL6 IL1B
47 kawasaki disease 29.7 TNF IL6 IL10
48 graft-versus-host disease 29.7 TNF IL6 IL1B IL10
49 acquired immunodeficiency syndrome 29.7 TNF IL6 IL1B IL10
50 q fever 29.6 TNF TLR4 IL6 IL1B IL10

Graphical network of the top 20 diseases related to Pertussis:



Diseases related to Pertussis

Symptoms & Phenotypes for Pertussis

UMLS symptoms related to Pertussis:


fever, pruritus, snoring, coughing

MGI Mouse Phenotypes related to Pertussis:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.44 ADCY10 ADORA1 FOS GNAI1 GNAQ GNAZ
2 hematopoietic system MP:0005397 10.4 FOS GNAI1 GNAQ GNAZ IL10 IL1B
3 behavior/neurological MP:0005386 10.37 ADORA1 FOS GNAI1 GNAQ GNAZ IL10
4 cardiovascular system MP:0005385 10.36 ADCY10 ADORA1 GNAQ IL10 IL1B IL6
5 cellular MP:0005384 10.31 ADCY10 FOS IL10 IL6 ITGAM ITGB2
6 immune system MP:0005387 10.31 FOS GNAI1 GNAQ IL10 IL1B IL6
7 integument MP:0010771 10.29 ADORA1 FOS GNAQ GNAZ IL10 IL1B
8 nervous system MP:0003631 10.28 ADORA1 FOS GNAI1 GNAQ GNAZ IL10
9 mortality/aging MP:0010768 10.27 ADORA1 FOS GNAQ GNAZ IL10 IL1B
10 normal MP:0002873 10.02 ADORA1 FOS GNA15 GNAQ IL10 ITGB2
11 neoplasm MP:0002006 9.98 FOS IL10 IL1B IL6 MAPK1 TLR4
12 no phenotypic analysis MP:0003012 9.91 ADCY10 GNAI1 IL10 JUN MAPK10 OPRM1
13 reproductive system MP:0005389 9.91 ADCY10 FOS GNAZ IL10 IL6 MAPK1
14 respiratory system MP:0005388 9.76 ADORA1 GNAQ IL10 IL6 JUN MAPK1
15 skeleton MP:0005390 9.7 FOS GNAI1 GNAQ IL10 IL1B IL6
16 vision/eye MP:0005391 9.23 FOS IL10 IL6 ITGB2 JUN MAPK1

Drugs & Therapeutics for Pertussis

Drugs for Pertussis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Montelukast Approved Phase 4 158966-92-8 5281040
2
Pentetic acid Approved Phase 4 67-43-6
3
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
4
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
5
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
6
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
7
BCG vaccine Investigational Phase 4
8 Cytochrome P-450 Enzyme Inducers Phase 4
9 Leukotriene Antagonists Phase 4
10 Immunologic Factors Phase 4
11 Vaccines Phase 4
12 Antidotes Phase 4
13 Diphtheria Antitoxin Phase 4
14 Antitoxins Phase 4
15 Tetanus Antitoxin Phase 4
16 Anti-Infective Agents Phase 4
17 Anti-Bacterial Agents Phase 4
18 Adjuvants, Immunologic Phase 4
19 Aluminum phosphate Phase 4
20 Chelating Agents Phase 4
21 Iron Chelating Agents Phase 4
22 Anticoagulants Phase 4
23 Calcium, Dietary Phase 4
24 Nutrients Phase 4
25 Micronutrients Phase 4
26 Trace Elements Phase 4
27 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
28 Chrysanthemum Phase 4
29 Antibodies Phase 4
30 Immunoglobulins Phase 4
31
Deferiprone Approved Phase 3 30652-11-0 2972
32
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
33
tannic acid Approved Phase 3 1401-55-4
34
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
35
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
36
Lactitol Investigational Phase 3 585-86-4, 585-88-6 493591
37 Rho(D) Immune Globulin Phase 3
38 gamma-Globulins Phase 3
39 Immunoglobulins, Intravenous Phase 3
40 Immunoglobulin G Phase 3
41 Hemagglutinins Phase 3
42 Cathartics Phase 3
43 Laxatives Phase 3
44 taxane Phase 3
45 Somatomedin B Phase 3
46 Fibrinolytic Agents Phase 3
47 Complement C3 Phase 3
48
Aluminum sulfate Approved Phase 1, Phase 2 10043-01-3
49
Ibuprofen Approved Phase 2 15687-27-1 3672
50 Benralizumab Approved, Investigational Phase 2 1044511-01-4

Interventional clinical trials:

(show top 50) (show all 404)
# Name Status NCT ID Phase Drugs
1 Safety and Immunogenicity of Adult Formulation Tetanus and Diphtheria Toxoids Adsorbed Combined With Acellular Pertussis (Tdap) Vaccine Following Blood and Morrow Transplantation in Adults Unknown status NCT00336115 Phase 4
2 Open Label Multicentric Randomized Phase IV Post Marketing Safety, Immunogenicity and Lot-to-Lot Consistency Analysis of Shan 5 [DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine] in Indian Infants Unknown status NCT00877357 Phase 4
3 Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand Unknown status NCT02408926 Phase 4
4 Impact of Pertussis Vaccination in Pregnancy on Maternal Protection Offered to Young Infants Unknown status NCT01698346 Phase 4
5 The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
6 Comparison of Two Vaccinal Schemes for DTP-Pertussis-Hib Primo-immunisation in Very Preterm-born Neonates: a Randomised Bicentric Controlled Study Unknown status NCT02179996 Phase 4
7 The Influence of BCG Vaccine as a Booster TDaP-IPV Vaccination: an Explorative Study Unknown status NCT02771782 Phase 4
8 An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age Unknown status NCT00870350 Phase 4
9 Clinical Study to Generate a Set of Data Characterising Clinical Events, Physiological Responses, and Innate and Adaptive Immune Responses Following a Single IM Immunisation With Boostrix® or Placebo in Healthy Adults Unknown status NCT02555540 Phase 4
10 A Double Blind Randomised Placebo Controlled Trial of Montelukast in the Treatment of Acute Persistent Cough in Young People and Adults in Primary Care Unknown status NCT01279668 Phase 4 Montelukast;Placebo
11 Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACEL™ and BOOSTRIX® Completed NCT00319553 Phase 4
12 Safety Among Adolescents and Adults of Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) 4 to 5 Years After a Previous Dose Completed NCT00347958 Phase 4
13 A Randomised Controlled Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants Completed NCT02145624 Phase 4 Repevax;Boostrix-IPV
14 An Open Label Multicentric Study to Evaluate the Immunogenicity and Safety of Indigenously Developed DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine (Shan 5) in Indian Infants. Completed NCT00617812 Phase 4
15 Immune Responses in Adults to Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose Completed NCT00712959 Phase 4
16 Regulatory Post-Marketing Surveillance (PMS) Study for ADACEL™ (Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined Vaccine for Adult) Completed NCT01137435 Phase 4
17 Evaluation of GSK Biologicals' dTpa Booster Vaccine in Young Adults 10 Years After Previous dTpa Boosting. Completed NCT00610168 Phase 4
18 Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) in Persons ≥65 Years of Age Completed NCT00457249 Phase 4
19 A Single Blind, Multicentric, Comparative, Vaccine Interchangeability Trial of Shan 5 (Liquid) and Easy Five (Liquid) [Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib Pentavalent Combination Vaccines] in Indian Infants. Completed NCT00674908 Phase 4
20 A Phase III/IV Randomised Open-label Study and Comparison of the Immunogenicity and Safety of a Single Adolescent Booster Dose of a Meningococcal Group C Conjugate-containing Booster Vaccine (Meningitec™, OR NeisVac-C™ , OR Menitorix™), When Given Concurrently With an Acellular Pertussis-containing Booster Vaccine (Repevax™ or IPV-Boostrix™) Completed NCT02526394 Phase 4 Pertussis containing vaccine
21 Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination Completed NCT00304265 Phase 4
22 Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting. Completed NCT00635128 Phase 4
23 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
24 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
25 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4
26 Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIM™(Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis) Completed NCT01437423 Phase 4
27 Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age. Completed NCT00514059 Phase 4 Boostrix polio
28 Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexa™ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02853929 Phase 4
29 Safety and Immunogenicity of Adacel® Vaccine Administered to Persons 10 Years of Age Completed NCT01311557 Phase 4
30 A Phase IV, Single-blind, Randomized, Controlled, Monocentric Study to Assess the Interchangeability of Quinvaxem (DTwP-HepB-Hib) as the 2nd and 3rd Dose After Initial Vaccination With Tritanrix HB+Hib (DTwP-HepB/Hib) With Respect to Safety and Immunogenicity in Healthy Infants at 6, 10 and 14 Weeks of Age Completed NCT01357720 Phase 4
31 A Prospective, Randomized, Open-label Clinical Trial to Assess the Safety and Immunogenicity of Simultaneous vs Sequential Administration of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and Inactivated Influenza Vaccine in Pregnant Women - Pilot Completed NCT02783170 Phase 4
32 Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
33 Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine) Completed NCT00777257 Phase 4
34 Safety and Immunogenicity of DAPTACEL® (CP10/5/5/3DT Aventis Pasteur 5-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ (HCP20/20/5/3DT-mIPV//PRP-T) Completed NCT00802867 Phase 4
35 Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
36 Phase IV, Open Label Trial to Evaluate Immunogenicity of Tdap Vaccine in Post-Partum Women to Optimize Vaccination Schedule for Women Who May Have a Subsequent Child Completed NCT01711645 Phase 4
37 Safety & Immunogenicity of a Booster Dose of dTPa Vaccine (Boostrix®) Co-admnd. With Aventis Pasteur's Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Vaccine (Menactra™) vs Admn. of Either Vaccine Alone in Healthy Adolescents Completed NCT00282295 Phase 4
38 Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexa™) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
39 Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM™) Given as a Booster Dose at 4 to 6 Years of Life in Children Previously Vaccinated With PENTAXIM™ in the Study E2I34 Completed NCT01031303 Phase 4
40 An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age. Completed NCT01659996 Phase 4
41 Non-specific Effects of Vaccines - In Search of the Immunological Background Completed NCT00168545 Phase 4
42 A Phase IV Study to Evaluate the Primary and Booster Immune Responses of UK Infants Receiving a Licensed 6-in-1 DTaP/IPV/Hib/HBV Vaccine (Infanrix-HexaTM) With a 13-valent Pneumococcal Conjugate Vaccine and Incorporating a Randomisation Study of a Single Dose of 3 Different Meningococcal Group C Conjugate Vaccines at 3 Months of Age Completed NCT01896596 Phase 4
43 A Phase IV, Randomized Study to Evaluate the Immune Response of UK Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life Completed NCT00625677 Phase 4
44 Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Japanese Healthy Infants Completed NCT01926015 Phase 4
45 Evaluation of GSK Biologicals' Boostrix™ Polio in Healthy Adults, 10 Years After a Booster Vaccination Completed NCT01323959 Phase 4
46 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix®) and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine (Gardasil®) in Healthy Adolescents When Administered With MenACWY Conjugate Vaccine Completed NCT01424644 Phase 4
47 Evaluation of GSK Biologicals' dTpa Booster Vaccine in Adults, Given 10 Years After Previous dTpa Boosting. Completed NCT00548171 Phase 4
48 An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of VAQTA™ Given Concomitantly With PedvaxHIB™ and Infanrix™ in Healthy Children 15 Months of Age Completed NCT00289913 Phase 4
49 A Phase 4, Randomized, Open-label Trial Evaluating the Safety, Tolerability, and Immunogenicity of DTaP Vaccine in Healthy Infants Given With a 7-valent Pneumococcal Conjugate Vaccine in Japan. Completed NCT01250756 Phase 4
50 Evaluation of GSK Biologicals' Boostrix™ in Healthy Adults, 10 Years After Previous Booster Vaccination Completed NCT01147900 Phase 4

Search NIH Clinical Center for Pertussis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Ampicillin
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)
Clarithromycin
Clostridium tetani toxoid antigen (formaldehyde inactivated)
Erythromycin
ERYTHROMYCIN PWDR
Guaifenesin

Cochrane evidence based reviews: bordetella infections

Genetic Tests for Pertussis

Anatomical Context for Pertussis

MalaCards organs/tissues related to Pertussis:

41
Neutrophil, Smooth Muscle, Endothelial, Testes, T Cells, Brain, Lung

The Foundational Model of Anatomy Ontology organs/tissues related to Pertussis:

19
Respiratory Tract

Publications for Pertussis

Articles related to Pertussis:

(show top 50) (show all 28024)
# Title Authors PMID Year
1
Determinants of delayed or incomplete diphtheria-tetanus-pertussis vaccination in parallel urban and rural birth cohorts of 30,956 infants in Tanzania. 38 17
30808282 2019
2
Lessons Learned from the Testing of Neonatal Vitamin A Supplementation. 38 17
30795563 2019
3
Neonatal Immunity to Bordetella pertussis Infection and Current Prevention Strategies. 38 17
30882004 2019
4
Bordetella pertussis antigens encapsulated into N-trimethyl chitosan nanoparticulate systems as a novel intranasal pertussis vaccine. 38
31240957 2019
5
Combined vaccines for prophylaxis of infectious conditions. 38
30829068 2019
6
Coptidis Rhizoma: a comprehensive review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. 38
30963783 2019
7
Mirtazapine increases glial cell line-derived neurotrophic factor production through lysophosphatidic acid 1 receptor-mediated extracellular signal-regulated kinase signaling in astrocytes. 38
31306636 2019
8
Endocytosis of CF in marginal cells of stria vascularis regulated by ROCK and MLCK signaling cascade, but not G-proteins. 38
30739815 2019
9
Orexin-A protects against oxygen-glucose deprivation/reoxygenation-induced cell damage by inhibiting endoplasmic reticulum stress-mediated apoptosis via the Gi and PI3K signaling pathways. 38
31233841 2019
10
Maternal Immunization in the U.S.: A Nationwide Retrospective Cohort Study. 38
31427034 2019
11
The BvgS PAS Domain, an Independent Sensory Perception Module in the Bordetella bronchiseptica BvgAS Phosphorelay. 38
31235515 2019
12
Epidemiology of pertussis in Marrakech and contribution of molecular diagnosis. 38
31274041 2019
13
PARPs and PAR as novel pharmacological targets for the treatment of stress granule-associated disorders. 38
31102582 2019
14
Immunogenicity of a Quadrivalent Human Papillomavirus Vaccine When Co-Administered with Tetanus-Reduced Diphtheria-Acellular Pertussis and Quadrivalent Meningococcal Conjugate Vaccines in Healthy Adolescents: Results from a Randomized, Observer-Blind, Controlled Trial. 38
31377946 2019
15
The 1925 Diphtheria Antitoxin Run to Nome - Alaska: A Public Health Illustration of Human-Animal Collaboration. 38
28032302 2019
16
Experimental autoimmune encephalomyelitis accelerates remyelination after lysophosphatidylcholine-induced demyelination in the corpus callosum. 38
31228686 2019
17
Vaccination Status in Pediatric Solid-Organ Transplant Recipients and Their Household Members. 38
31050613 2019
18
Trends in governmental expenditure on vaccination programmes in the Netherlands, a historical analysis. 38
31420172 2019
19
Safety, equity and monitoring: A review of the gaps in maternal vaccination strategies for Aboriginal and Torres Strait Islander women. 38
31368832 2019
20
Pertussis in Latin America: Recent epidemiological data presented at the 2017 Global Pertussis Initiative meeting. 38
31331774 2019
21
New Pertussis Vaccines: A Need and a Challenge. 38
31432399 2019
22
T3S injectisome needle complex structures in four distinct states reveal the basis of membrane coupling and assembly. 38
31427728 2019
23
WNT-3A-induced β-catenin signaling does not require signaling through heterotrimeric G proteins. 38
31235524 2019
24
Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: A meeting report. 38
31377079 2019
25
Shaping markets to benefit global health - A 15-year history and lessons learned from the pentavalent vaccine market. 38
31384748 2019
26
Role of mPRα (PAQR7) in progesterone-induced Ca2+ decrease in human vascular smooth muscle cells. 38
31416049 2019
27
A systematic assessment of current genome-scale metabolic reconstruction tools. 38
31391098 2019
28
Further investigations of the IgE response to tetanus and diphtheria following covaccination with acellular rather than cellular Bordetella pertussis. 38
31419322 2019
29
Vaccine acquired pertussis immunity was weakened at 4 years of age and asymptomatic pertussis infection was suspected based on serological surveillance. 38
31053536 2019
30
Role of Major Toxin Virulence Factors in Pertussis Infection and Disease Pathogenesis. 38
31376138 2019
31
The effectiveness of maternal pertussis vaccination in protecting newborn infants in Brazil: A case-control study. 38
30948222 2019
32
Association between the timing of maternal vaccination and newborns' anti-pertussis toxin antibody levels. 38
31153689 2019
33
Questionnaire survey on maternal pertussis vaccination for pregnant women and mothers in Nara prefecture, Japan. 38
31368853 2019
34
Proper pertussis vaccination will probably not increase vaccination coverage: a case-control study. 38
31426872 2019
35
Functional Programming of Innate Immune Cells in Response to Bordetella pertussis Infection and Vaccination. 38
31432398 2019
36
The unmet need for pertussis prevention in patients with chronic obstructive pulmonary disease in the Italian context. 38
31403385 2019
37
Patch testing children with aluminium chloride hexahydrate in petrolatum: A review and a recommendation. 38
31066081 2019
38
Evaluation of Educational Interventions to Enhance Adolescent Specific Vaccination Coverage. 38
31161606 2019
39
Activation of somatostatin receptor 5 suppresses T-type Ca2+ channels through NO/cGMP/PKG signaling pathway in rat retinal ganglion cells. 38
31220522 2019
40
Current situation, causes, and countermeasures to NIP vaccine shortages in Guangzhou, China. 38
31403888 2019
41
Streptococcus pneumoniae and Haemophilus influenzae nasopharyngeal molecular detection in children with acute respiratory tract infection in SANADOR Hospital, Romania. 38
31389781 2019
42
Randomized Controlled Trial on the Effects of Morning versus Evening Primary Vaccination on Episodes of Hypoxemia and Bradycardia in Very Preterm Infants. 38
31394525 2019
43
Role of Lysophosphatidic Acid in Vascular Smooth Muscle Cell Proliferation. 38
31369714 2019
44
Cannabichromene is a cannabinoid CB2 receptor agonist. 38
31368508 2019
45
Insurance Reimbursements for Routinely Recommended Adult Vaccines in the Private Sector. 38
31248743 2019
46
Shotgun proteomic analysis of Bordetella parapertussis provides insights into the physiological response to iron starvation and potential new virulence determinants absent in Bordetella pertussis. 38
31325608 2019
47
Knowledge, attitudes, beliefs and practices of obstetrics-gynecologists on seasonal influenza and pertussis immunizations in pregnant women: preliminary results from North-Western Italy. 38
30938116 2019
48
Impact of nutritional supplementation during pregnancy on antibody responses to diphtheria-tetanus-pertussis vaccination in infants: A randomised trial in The Gambia. 38
31386660 2019
49
Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. 38
31418814 2019
50
Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region. 38
31328999 2019

Variations for Pertussis

Expression for Pertussis

Search GEO for disease gene expression data for Pertussis.

Pathways for Pertussis

Pathways related to Pertussis according to GeneCards Suite gene sharing:

(show top 50) (show all 195)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.19 TNF TLR4 OPRM1 MAPK10 MAPK1 JUN
2
Show member pathways
14.04 TNF MAPK10 MAPK1 JUN ITGB2 ITGAM
3
Show member pathways
14.02 TNF MAPK10 MAPK1 JUN ITGB2 ITGAM
4
Show member pathways
13.89 MAPK10 MAPK1 JUN ITGB2 ITGAM IL6
5
Show member pathways
13.85 TNF TLR4 MAPK10 MAPK1 JUN IL6
6
Show member pathways
13.72 TNF MAPK10 MAPK1 JUN IL6 IL1B
7
Show member pathways
13.72 TNF MAPK10 MAPK1 JUN ITGB2 ITGAM
8
Show member pathways
13.59 MAPK10 MAPK1 JUN ITGB2 ITGAM GNAZ
9
Show member pathways
13.54 TNF OPRM1 MAPK1 ITGB2 ITGAM IL6
10
Show member pathways
13.54 TNF TLR4 MAPK10 ITGB2 ITGAM IL6
11
Show member pathways
13.48 SERPING1 MAPK1 ITGB2 ITGAM GNAQ GNAI1
12
Show member pathways
13.47 TNF MAPK10 MAPK1 JUN IL6 IL1B
13
Show member pathways
13.42 TNF MAPK10 MAPK1 JUN IL6 GNAI1
14
Show member pathways
13.41 TNF TLR4 MAPK10 MAPK1 JUN IL1B
15
Show member pathways
13.27 MAPK10 MAPK1 JUN GNAZ GNAI1 GNA15
16
Show member pathways
13.26 OPRM1 MAPK1 GNAZ GNAQ GNAI1 GNA15
17
Show member pathways
13.25 MAPK1 ITGB2 ITGAM IL6 GNAZ GNAI1
18
Show member pathways
13.24 MAPK10 MAPK1 JUN IL6 GNAI1 GNA15
19
Show member pathways
13.23 OPRM1 MAPK10 MAPK1 JUN GNAQ GNAI1
20
Show member pathways
13.22 MAPK10 MAPK1 JUN GNAZ GNAQ GNAI1
21
Show member pathways
13.2 MAPK1 JUN GNAZ GNAI1 GNA15 GNA14
22
Show member pathways
13.19 MAPK10 JUN ITGB2 ITGAM GNAZ GNAI1
23
Show member pathways
13.17 TNF MAPK10 MAPK1 JUN IL6 GNAZ
24
Show member pathways
13.15 TNF TLR4 MAPK10 MAPK1 JUN IL6
25
Show member pathways
13.14 TNF TLR4 MAPK10 MAPK1 JUN IL6
26
Show member pathways
13.13 TNF MAPK10 MAPK1 JUN ITGB2 ITGAM
27
Show member pathways
13.13 TNF MAPK10 MAPK1 JUN ITGB2 GNAZ
28
Show member pathways
13.08 MAPK10 MAPK1 JUN GNAI1 GNA15 GNA14
29
Show member pathways
13.07 TNF MAPK1 ITGB2 IL6 IL1B IL10
30
Show member pathways
13.06 MAPK10 MAPK1 JUN ITGB2 ITGAM FOS
31
Show member pathways
13.06 MAPK10 MAPK1 JUN ITGB2 ITGAM IL6
32 13.03 MAPK10 MAPK1 JUN IL6 GNAQ GNAI1
33
Show member pathways
12.95 MAPK1 ITGB2 ITGAM GNAI1 FOS
34
Show member pathways
12.95 MAPK10 MAPK1 JUN ITGB2 ITGAM GNAZ
35 12.94 TNF MAPK10 MAPK1 JUN IL1B FOS
36
Show member pathways
12.93 TNF MAPK10 MAPK1 JUN FOS
37
Show member pathways
12.91 TNF MAPK1 JUN IL6 FOS
38
Show member pathways
12.91 MAPK10 MAPK1 ITGB2 ITGAM GNAQ GNAI1
39
Show member pathways
12.89 TNF TLR4 MAPK10 IL6 IL1B
40
Show member pathways
12.88 MAPK10 MAPK1 JUN IL1B GNAZ GNAQ
41
Show member pathways
12.86 TNF MAPK10 MAPK1 JUN IL1B FOS
42
Show member pathways
12.84 TNF MAPK10 MAPK1 JUN IL10 GNA15
43
Show member pathways
12.83 MAPK10 MAPK1 JUN IL6 FOS
44
Show member pathways
12.83 TNF TLR4 MAPK10 MAPK1 JUN IL1B
45
Show member pathways
12.81 MAPK1 GNAZ GNAI1 GNA15 GNA14
46
Show member pathways
12.8 TNF MAPK10 MAPK1 JUN FOS
47
Show member pathways
12.79 TNF MAPK1 IL6 IL1B IL10 FOS
48
Show member pathways
12.78 TNF TLR4 MAPK10 MAPK1 JUN IL6
49
Show member pathways
12.77 MAPK1 JUN GNAZ GNAI1 GNA15 GNA14
50
Show member pathways
12.76 OPRM1 MAPK10 MAPK1 GNAQ GNAI1 ADORA1

GO Terms for Pertussis

Cellular components related to Pertussis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.35 TNF OPRM1 ITGB2 ITGAM GNAI1
2 transcription factor AP-1 complex GO:0035976 9.32 JUN FOS
3 integrin alphaM-beta2 complex GO:0034688 9.16 ITGB2 ITGAM
4 heterotrimeric G-protein complex GO:0005834 9.02 GNAZ GNAQ GNAI1 GNA15 GNA14
5 plasma membrane GO:0005886 10.1 TNF TLR4 OPRM1 MAPK10 MAPK1 ITGB2

Biological processes related to Pertussis according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Name GO ID Score Top Affiliating Genes
1 aging GO:0007568 9.98 SERPING1 JUN ITGB2 IL10 FOS
2 Fc-epsilon receptor signaling pathway GO:0038095 9.96 MAPK10 MAPK1 JUN FOS
3 positive regulation of DNA-binding transcription factor activity GO:0051091 9.96 TNF IL6 IL1B IL10
4 cellular response to lipopolysaccharide GO:0071222 9.96 TNF TLR4 IL6 IL1B IL10
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.94 TNF TLR4 OPRM1 JUN
6 positive regulation of JNK cascade GO:0046330 9.92 TNF TLR4 IL1B
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.92 TNF TLR4 ITGB2 IL6 IL1B
8 apoptotic signaling pathway GO:0097190 9.9 TNF TLR4 ADORA1
9 positive regulation of smooth muscle cell proliferation GO:0048661 9.89 TNF JUN IL6
10 activation of MAPK activity GO:0000187 9.89 TNF TLR4 MAPK10 MAPK1 IL1B
11 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 TNF TLR4 IL1B
12 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.88 TNF JUN IL10
13 positive regulation of interferon-gamma production GO:0032729 9.87 TNF TLR4 IL1B
14 cellular response to organic substance GO:0071310 9.87 MAPK10 MAPK1 IL1B
15 cellular response to cadmium ion GO:0071276 9.85 MAPK1 JUN FOS
16 cellular response to reactive oxygen species GO:0034614 9.85 MAPK1 JUN FOS
17 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.85 OPRM1 GNAZ GNAI1 ADORA1
18 platelet activation GO:0030168 9.85 MAPK1 IL6 GNAQ GNA15 GNA14
19 regulation of sensory perception of pain GO:0051930 9.84 OPRM1 IL10 ADORA1
20 positive regulation of interleukin-6 production GO:0032755 9.84 TNF TLR4 IL6 IL1B
21 negative regulation of interleukin-6 production GO:0032715 9.83 TNF TLR4 IL10
22 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.82 JUN IL10 FOS
23 positive regulation of interleukin-8 production GO:0032757 9.82 TNF TLR4 IL1B
24 negative regulation of neurogenesis GO:0050768 9.81 TNF IL6 IL1B
25 positive regulation of nitric oxide biosynthetic process GO:0045429 9.81 TNF TLR4 ITGB2 IL1B
26 regulation of DNA-binding transcription factor activity GO:0051090 9.8 MAPK1 JUN FOS
27 positive regulation of chemokine production GO:0032722 9.79 TNF TLR4 IL6
28 toll-like receptor 4 signaling pathway GO:0034142 9.79 TLR4 ITGB2 ITGAM
29 positive regulation of glial cell proliferation GO:0060252 9.78 TNF IL6 IL1B
30 negative regulation of lipid catabolic process GO:0050995 9.77 TNF IL1B ADORA1
31 inflammatory response GO:0006954 9.76 TNF TLR4 ITGB2 IL6 IL1B IL10
32 response to glucocorticoid GO:0051384 9.75 TNF IL6 IL10
33 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.74 ITGB2 ITGAM
34 amyloid-beta clearance GO:0097242 9.74 ITGB2 ITGAM
35 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.74 TNF TLR4
36 negative regulation of synaptic transmission GO:0050805 9.74 IL1B GNAI1
37 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.74 TNF IL1B IL10
38 negative regulation of lipid storage GO:0010888 9.73 TNF IL6
39 positive regulation of chemokine biosynthetic process GO:0045080 9.73 TNF IL1B
40 endothelial cell apoptotic process GO:0072577 9.73 TNF IL10
41 positive regulation of neuron death GO:1901216 9.73 ITGB2 ITGAM FOS ADORA1
42 regulation of establishment of endothelial barrier GO:1903140 9.72 TNF IL1B
43 positive regulation of MHC class II biosynthetic process GO:0045348 9.72 TLR4 IL10
44 positive regulation of lipid catabolic process GO:0050996 9.72 IL1B ADORA1
45 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.71 GNA15 GNA14
46 negative regulation of cytokine secretion involved in immune response GO:0002740 9.71 TNF IL10
47 lipopolysaccharide-mediated signaling pathway GO:0031663 9.71 TNF TLR4 MAPK1 IL1B
48 positive regulation of fever generation GO:0031622 9.7 TNF IL1B
49 sequestering of triglyceride GO:0030730 9.69 TNF IL1B
50 positive regulation of neutrophil degranulation GO:0043315 9.69 ITGB2 ITGAM

Molecular functions related to Pertussis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 GTP binding GO:0005525 9.85 GNAZ GNAQ GNAI1 GNA15 GNA14
2 cytokine activity GO:0005125 9.8 TNF IL6 IL1B IL10
3 protein heterodimerization activity GO:0046982 9.8 TLR4 JUN ITGB2 ITGAM FOS ADORA1
4 GTPase activity GO:0003924 9.77 GNAZ GNAQ GNAI1 GNA15 GNA14
5 heat shock protein binding GO:0031072 9.65 ITGB2 ITGAM ADORA1
6 G protein-coupled receptor binding GO:0001664 9.63 GNAZ GNAQ GNAI1 GNA15 GNA14 ADORA1
7 G protein-coupled serotonin receptor binding GO:0031821 9.43 GNAZ GNAI1
8 complement component C3b binding GO:0001851 9.4 ITGB2 ITGAM
9 guanyl nucleotide binding GO:0019001 9.35 GNAZ GNAQ GNAI1 GNA15 GNA14
10 G-protein beta/gamma-subunit complex binding GO:0031683 9.1 GNAZ GNAQ GNAI1 GNA15 GNA14 ADORA1
11 protein binding GO:0005515 10.21 TNF TLR4 SERPING1 OPRM1 MAPK10 MAPK1

Sources for Pertussis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....